Status:
COMPLETED
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5%...
Eligibility Criteria
Inclusion
- Ocular hypertension or glaucoma that requires treatment with medication
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Exclusion
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT01881126
Start Date
June 1 2013
End Date
October 1 2014
Last Update
November 30 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrie, Ontario, Canada
2
Toronto, Ontario, Canada